Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Disruption of the systemic angiogenesis balance to favor enhanced angiogenesis is speculated to represent a key step in the growth of tumors. Although a major emphasis has been placed on the increase of angiogenesis stimulators, such as VEGF, on the disruption of the angiogenic balance, the potential role of the physiological levels of endogenous inhibitors of angiogenesis on tumor growth is poorly understood. Here, we use three independent lines of mice deficient in tumstatin, endostatin, or thrombospondin-1 (TSP-1), to address the role that these endogenous angiogenesis inhibitors play in tumor growth. Our experiments demonstrate that normal physiological levels of these inhibitors serve to retard the growth of tumors, and that their absence leads to enhanced angiogenesis and a 2- to 3-fold increase in tumor growth. The tumor-suppressive action of TSP-1, endostatin, and tumstatin correlates with expression of CD36 receptor, α5β1 integrin, and αvβ3 integrin on proliferating endothelial cells, respectively. Moreover, tumors grow 2-fold faster in the tumstatin/TSP-1 double-knockout mice, compared with either the tumstatin- or the TSP-1-deficient mice, strongly suggesting that ceiling rate of cancer growth is not completely dependent on the genetic defects of cancer cells but also depends on the host-derived tumor microenvironment. Additionally, tumor growth in transgenic mice overproducing endostatin specifically in the endothelial cells (a 1.6-fold increase in the circulating levels; mimicking Down's syndrome condition) is 3-fold slower than the tumor growth in wild-type mice. Collectively, our data suggest that physiological levels of endogenous inhibitors of angiogenesis can serve as endothelium-specific tumor suppressors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Cited by
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Matrix metalloproteinases and the regulation of tissue remodelling
Page-McCaw, A., Ewald, A. J., & Werb, Z. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2125 · Cited by 2,630
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Biological properties of “naked” metal nanoparticles☆
BHATTACHARYA, R., & MUKHERJEE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.013 · Cited by 917
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
FOLKMAN, J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 658
Endogenous Inhibitors of Angiogenesis
Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 553
Self-citationRegulation of angiogenesis: Wound healing as a model
EMING, S., BRACHVOGEL, B., ODORISIO, T., & KOCH, M. (2007) · Progress in Histochemistry and Cytochemistry · doi:10.1016/j.proghi.2007.06.001 · Cited by 392
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
Kuo, D. S., Labelle-Dumais, C., & Gould, D. B. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds346 · Cited by 320
Cell–matrix adhesion in vascular development
HYNES, R. O. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02569.x · Cited by 261
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Shi, H., Huang, Y., Zhou, H., Song, X., Yuan, S., Fu, Y., & Luo, Y. (2007) · Blood · doi:10.1182/blood-2007-01-064428 · Cited by 258
Cell-matrix interactions in dermal repair and scarring
Eckes, B., Nischt, R., & Krieg, T. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-4 · Cited by 205
“It is an inhibitor of angiogenesis and has been intensively investigated as an anti-angiogenic peptide in tumor models [8].”
BackgroundEndogenous inhibitors of angiogenesis
Ribatti, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.019 · Cited by 191
Greenaway, J., Lawler, J., Moorehead, R., Bornstein, P., LaMarre, J., & Petrik, J. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20904 · Cited by 187
“The signaling pathway that leads to apoptosis includes recruitment of the Src-family tyrosine kinase, p59fyn, and the activation of p38 stress kinase and caspases (Jimenez et al., 2000; Yano et al., 2002; Sund et al., 2005).”
BackgroundSelf-citationEnhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells
Wang, Y., Wang, S., & Sheibani, N. (2006) · Microvascular Research · doi:10.1016/j.mvr.2006.02.004 · Cited by 34
The history of angiogenesis inhibitors
Ribatti, D. (2007) · Leukemia · doi:10.1038/sj.leu.2404756 · Cited by 15
Metadata
- Authors
- Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M., Yerramalla, U., Benjamin, L. E., Lawler, J., Kieran, M., Shah, A., & Kalluri, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-02-14
- Volume
- 102
- Issue
- 8
- Pages
- 2934-2939
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2080071499
- Cited by
- 179
- References
- 4
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.